{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T12:50:34Z","timestamp":1783515034958,"version":"3.55.0"},"reference-count":32,"publisher":"Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Infect Dis"],"published-print":{"date-parts":[[2025,11,28]]},"DOI":"10.7883\/yoken.jjid.2023.409","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T18:09:33Z","timestamp":1745950173000},"page":"204-210","source":"Crossref","is-referenced-by-count":1,"title":["Incidence and Factors Associated with HIV Virologic Failure among Adults Undergoing First-Line Antiretroviral Therapy: a Five-Year Retrospective Study in Thailand"],"prefix":"10.7883","volume":"78","author":[{"given":"Lantharita","family":"Charoenpong","sequence":"first","affiliation":[{"name":"Department of Medicine, Bamrasnaradura Infectious Diseases Institute, Department of Diseases Control, Ministry of Public Health, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalor","family":"Santiwarangkana","sequence":"additional","affiliation":[{"name":"National Health Security Office Region 4, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weerawat","family":"Manosuthi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Bamrasnaradura Infectious Diseases Institute, Department of Diseases Control, Ministry of Public Health, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4631","reference":[{"key":"1","unstructured":"1. The Joint United Nations Programme on HIV and AIDS. Global HIV & AIDS statistics-fact sheet. Available at <https:\/\/www.unaids.org\/en\/resources\/fact-sheet>. Accessed October 30, 2023."},{"key":"2","unstructured":"2. The Joint United Nations Programme on HIV and AIDS. Countries fact sheets Thailand 2022. Available at <https:\/\/www.unaids.org\/en\/regionscountries\/countries\/thailand>. Accessed October 30, 2023."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Manosuthi W, Ongwandee S, Bhakeecheep S, et al. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand. AIDS Res Ther. 2015;12:12.","DOI":"10.1186\/s12981-015-0053-z"},{"key":"4","unstructured":"4. Division of AIDS and STIs, Department of Disease Control, Thailand. HIV Info HUB. Available at <https:\/\/hivhub.ddc.moph.go.th\/officer\/response.php>. Accessed October 30, 2023."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.","DOI":"10.1056\/NEJM199803263381301"},{"key":"6","unstructured":"6. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14:281-290. Erratum in Lancet Infect Dis. 2014;14:269."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Sutthent R, Arworn D, Kaoriangudom S, et al. HIV-1 drug resistance in Thailand: before and after national access to antiretroviral program. J Clin Virol. 2005;34:272-276.","DOI":"10.1016\/j.jcv.2005.02.014"},{"key":"8","unstructured":"8. Iemwimangsa N, Pasomsub E, Sukasem C, et al. Surveillance of HIV-1 drug-resistance mutation in Thailand from 1999 to 2014. Southeast Asian J Trop Med Public Health. 2017;48:271-281."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Thanprasertsuk S, Phokhasawad K, Teeraratkul A, et al. HIV drug resistance among pre-treatment cases in Thailand: four rounds of surveys during 2006\u20132013. Outbreak Surveill Investig Rep. 2018;11:6-13.","DOI":"10.59096\/osir.v11i1.263071"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Zhou Y, Lu J, Wang J, et al. Prevalence of HIV antiretroviral drug resistance and its impacts on HIV-1 virological failures in Jiangsu, China: a cross-sectional study. BioMed Res Int. 2016;2016:1752437.","DOI":"10.1155\/2016\/1752437"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hailu GG, Hagos DG, Hagos AK, et al. Virological and immunological failure of HAART and associated risk factors among adults and adolescents in the Tigray region of Northern Ethiopia. PLoS One. 2018;13:e0196259.","DOI":"10.1371\/journal.pone.0196259"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ekong E, Ndembi N, Okonkwo P, et al. Epidemiologic and viral predictors of antiretroviral drug resistance among persons living with HIV in a large treatment program in Nigeria. AIDS Res Ther. 2020;17:7.","DOI":"10.1186\/s12981-020-0261-z"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Khienprasit N, Chaiwarith R, Sirisanthana T, et al. Incidence and risk factors of antiretroviral treatment failure in treatment-na\u00efve HIV-infected patients at Chiang Mai University Hospital, Thailand. AIDS Res Ther. 2011;8:42.","DOI":"10.1186\/1742-6405-8-42"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Xing H, Wang X, Liao L, et al. Incidence and associated factors of HIV drug resistance in Chinese HIV-infected patients receiving antiretroviral treatment. PLoS One. 2013;8:e62408.","DOI":"10.1371\/journal.pone.0062408"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Fogel JM, Hudelson SE, Ou SS, et al. Brief report: HIV drug resistance in adults failing early antiretroviral treatment: results from the HIV prevention trials network 052 trial. J Acquir Immune Defic Syndr. 2016;72:304-309.","DOI":"10.1097\/QAI.0000000000000951"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Lu X, Zhao H, Zhang Y, et al. HIV-1 drug-resistant mutations and related risk factors among HIV-1-positive individuals experiencing treatment failure in Hebei Province, China. AIDS Res Ther. 2017;14:4.","DOI":"10.1186\/s12981-017-0133-3"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ahmed M, Merga H, Jarso H. Predictors of virological treatment failure among adult HIV patients on first-line antiretroviral therapy in Woldia and Dessie hospitals, Northeast Ethiopia: a case-control study. BMC Infect Dis. 2019;19:305.","DOI":"10.1186\/s12879-019-3924-4"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Hailu GG, Hagos DG, Hagos AK, et al. Virological and immunological failure of HAART and associated risk factors among adults and adolescents in the Tigray region of Northern Ethiopia. PLoS One. 2018;13:e0196259.","DOI":"10.1371\/journal.pone.0196259"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Palumbo PJ, Fogel JM, Hudelson SE, et al. HIV drug resistance in adults receiving early vs. delayed antiretroviral therapy: HPTN 052. J Acquir Immune Defic Syndr. 2018;77:484-491.","DOI":"10.1097\/QAI.0000000000001623"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Zuo L, Liu K, Liu H, et al. Trend of HIV-1 drug resistance in China: a systematic review and meta-analysis of data accumulated over 17 years (2001\u20132017) EClinicalMedicine. 2020;18:100238. Erratum in EClinicalMedicine. 2021;33:100696.","DOI":"10.1016\/j.eclinm.2020.100696"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Nasomsong W, Phokaphol K, Changpradub D. First-line antiretroviral regimen failure and determinants in an urban HIV clinic at Phramongkutklao Hospital, Bangkok, Thailand: 20 years experience, HIV AIDS (Auckl). 2021;13:261-269.","DOI":"10.2147\/HIV.S295512"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Pillay P, Ford N, Shubber Z, et al. Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis. PLoS One. 2013;8:e68995.","DOI":"10.1371\/journal.pone.0068995"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-260.","DOI":"10.1056\/NEJMoa051871"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Nachega JB, Marconi VC, van Zyl GU, et al. HIV treatment adherence, drug resistance, virologic failure: evolving concepts. Infect Disord Drug Targets. 2011;11:167-174.","DOI":"10.2174\/187152611795589663"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Stirrup OT, Sabin CA, Phillips AN, et al. Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV. J Virus Erad. 2019;5:204-211.","DOI":"10.1016\/S2055-6640(20)30037-6"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Mziray SR, Kumburu HH, Assey HB, et al. Patterns of acquired HIV-1 drug resistance mutations and predictors of virological failure in Moshi, Northern Tanzania. PLoS One. 2020;15:e0232649.","DOI":"10.1371\/journal.pone.0232649"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Dowshen N, D\u2019Angelo L. Health care transition for youth living with HIV\/AIDS. Pediatrics. 2011;128:762-771.","DOI":"10.1542\/peds.2011-0068"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Reif LK, Abrams EJ, Arpadi S, et al. Interventions to improve antiretroviral therapy adherence among adolescents and youth in low- and middle-income countries: a systematic review 2015\u20132019. AIDS Behav. 2020;24:2797-2810.","DOI":"10.1007\/s10461-020-02822-4"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Ning C, Smith KM, McCan n CD, et al. Outcome of sentinel hospital-based and CDC-based ART service delivery: a prospective open cohort of people living with HIV in China. Sci. Rep. 2017;7:42637.","DOI":"10.1038\/srep42637"},{"key":"30","unstructured":"30. Ruxrungtham K, Chokephaibulkit K, Chetchotisakd P, et al. Thailand National Guidelines on HIV\/AIDS Treatment and Prevention 2021\/2022. Nonthaburi: Division of AIDS and STIs, Department of Disease Control; 2022. Available at <https:\/\/www.thaiaidssociety.org\/wp-content\/uploads\/2022\/10\/HIV-AIDS-Guideline-2564_2565.pdf>. Accessed October 29, 2025. Thai."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Zhao AV, Crutchley RD, Guduru RC, et al. A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection. Retrovirology. 2022;19:22.","DOI":"10.1186\/s12977-022-00608-1"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Choi JY, Poonkasetwattana M, Phanuphak N, et al. Overcoming challenges across the HIV care continuum in the Asia- Pacific region: expert recommendations. BMJ Glob Health. 2023;8:e012722.","DOI":"10.1136\/bmjgh-2023-012722"}],"container-title":["Japanese Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/78\/6\/78_JJID.2023.409\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T03:58:06Z","timestamp":1763783886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/78\/6\/78_JJID.2023.409\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.7883\/yoken.jjid.2023.409","relation":{},"ISSN":["1344-6304","1884-2836"],"issn-type":[{"value":"1344-6304","type":"print"},{"value":"1884-2836","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"article-number":"JJID.2023.409"}}